Chapter 2 · Getting the data ready
What do you do about missing values?
Why data go missing, complete-case analysis, single and multiple imputation, and sensitivity analysis.
Read first: Data collection, Clinical trials
The problem first
You are a third-year Psychiatry resident. Your thesis trial randomised 120 patients with depression to an add-on drug or placebo and recorded the HAM-D score at baseline, 6 weeks and 12 weeks. At 12 weeks, 28 patients have no score, 19 of them on placebo.
The software runs the t-test on the 92 patients with complete data without any warning. A co-resident suggests filling each gap with the patient's 6-week score. At the pre-submission seminar, the examiner turns to the flow diagram.
“Why are these 28 patients missing, and would your conclusion survive if they had done worse?”
Start here
Why does it matter which patients are missing?
Missing values cause two problems. There are fewer patients, so the estimate is less precise. And if the missing patients differ from the others, the estimate is biased, however many patients remain.
Three types of missing data
Why are the values missing?
The reason decides which analysis gives an unbiased answer. The three standard terms come from Rubin's framework for missing data.
- Missing completely at random (MCAR): the chance of a value being missing is unrelated to anything about the patient, recorded or not. A freezer failure destroys a batch of samples. The patients left are a random subset, so a complete-case analysis loses precision but is not biased.
- Missing at random (MAR): the chance depends on things you have recorded, and not further on the missing value. Older patients miss the 1-year visit more often, age is recorded, and among patients of the same age attendance is unrelated to the result. Methods that use age can correct the bias.
- Missing not at random (MNAR): the chance still depends on the missing value after allowing for everything recorded. Patients whose mood worsens stop answering the questionnaire. No recorded variable explains it.
The names mislead. “Missing at random” does not mean the missing patients are like the others: in the MAR example they are older. As Sterne and colleagues put it, the phrases convey little about their technical meaning. More important for practice: it is not possible to distinguish MAR from MNAR using the observed data, so the assumption has to be argued from how the data were collected and then tested with sensitivity analyses.
Interactive
Remove BP values by each mechanism and watch the complete-case mean, the imputed SD and the true mean
The same 200 made-up patients each time. Only the reason for the missing values changes.
Try this: keep 30% missing and switch between MCAR, MAR and MNAR. Watch the complete-case mean and the mean filled in from age, compared with the true mean of all 200 patients.
Teaching example with made-up data. In a real study you never see the true mean or the missing values. The simulation shows them so that you can see the bias.
Out of 200 patients
Older patients miss the visit more often. Age is recorded for everyone, so the missing BP values can be predicted from age.
| Estimate of mean BP | mmHg | Difference from the true mean |
|---|---|---|
| True mean, all 200 patients | 141.4 | – |
| Complete cases only (140 patients) | 135.3 | -6.1 |
| Missing values predicted from age (regression) | 141.4 | +0.0 |
SD of BP: true 17.5 · after filling every gap with the complete-case mean 12.6
Interactive
Read each scenario and name the mechanism: MCAR, MAR or MNAR
Look for the one fact that decides it: is missingness linked to nothing, to something recorded, or to the missing value itself?
Try this: for each scenario, decide why the values are missing. The explanation appears after you choose, and you can change your answer.
Made-up scenarios. In a real study you cannot prove which mechanism applies. You judge it from how the data were collected.
A freezer failure destroyed one batch of stored serum samples. The batch held samples from patients enrolled on those days, and enrolment day was unrelated to the patients or their results.
In a cohort, older patients miss the 1-year visit more often. Age is recorded for everyone. Among patients of the same age, missing the visit is unrelated to their 1-year result.
In a depression trial, patients whose mood has worsened since the last visit stop answering the questionnaire. Nothing recorded so far predicts who worsens.
In a survey, people with the highest incomes leave the income question blank more often than others with the same education, job and age.
In a diabetes registry, HbA1c is missing more often in patients from rural centres. The centre is recorded. Within a centre, whether HbA1c was measured is unrelated to its value.
The research assistant was on leave for two weeks and nobody collected the questionnaires of patients seen in that period. The leave dates were unrelated to the patients.
Comparison
Missing at random or missing not at random: what is the difference?
| Feature | Missing at random (MAR) | Missing not at random (MNAR) |
|---|---|---|
| Missingness depends on | Variables you have recorded | The missing value itself, even after allowing for recorded variables |
| Clinical example | Older patients miss the follow-up visit; age is recorded | Patients whose mood worsened stop answering the questionnaire |
| Complete-case analysis | Often biased (unbiased in some special cases, below) | Biased |
| Multiple imputation | Unbiased if the imputation model includes the variables that predict missingness | Its bias may be as big as or bigger than that of complete cases |
| Can the data tell you which? | No. MAR and MNAR cannot be distinguished using observed data | No |
| What to do | Multiple imputation or a mixed model as the primary analysis | Sensitivity analyses under a range of MNAR assumptions |
The default
What does your software do with a missing value?
Most procedures silently drop every patient with a missing value in any variable the analysis uses. This is complete-case (listwise) analysis. In R, lm() does this by default.
When a complete-case analysis is acceptable
- Data are MCAR. The estimate is not biased, only less precise.
- Only the outcome is missing, measured once, and all variables associated with the outcome being missing are included as covariates (under MAR). Sterne and colleagues note that such analyses will not be biased.
- Only predictors are missing, for reasons unrelated to the outcome. There is no bias, but multiple imputation can recover lost precision.
- Very little is missing. Jakobsen and colleagues give a rule of thumb: complete-case analysis may be the primary analysis if under about 5% is missing and particular patient groups (the very sick or the very well) are not lost from one of the compared groups.
Otherwise complete-case analysis carries a risk of overestimating benefit and underestimating harm. It is still the most common approach: in 77 trials published in 2013 in the BMJ, JAMA, Lancet and NEJM, 73 had missing outcome data and 33 of those used complete cases for the primary analysis (Bell et al., 2014).
Single imputation
Why does filling in the mean or the last value mislead?
Both give every missing patient one invented value and then analyse it as if it had been measured.
- Mean imputation puts every missing value at the centre, which reduces the variability of the data.
- LOCF and baseline observation carried forward give unbiased estimates only under restrictive assumptions. Depending on the disease and who drops out, LOCF can make a treatment look better or worse, and it is not always conservative (EMA, 2010).
- Every single-imputation method treats invented values as real, so standard errors are too small (Sterne et al., 2009). The NRC panel recommended that LOCF and baseline observation carried forward should not be used as the primary approach unless their assumptions are scientifically justified.
Multiple imputation
How does multiple imputation fill the gaps without pretending to know the values?
It fills each gap several times with different plausible values, analyses every completed dataset, and combines the results so that the uncertainty about the missing values is included in the standard error.
- Choose the imputation model: predict each variable with missing values from the others. Include the outcome, every variable in the planned analysis, and variables that predict the missing values or the reason they are missing.
- Create m completed datasets. Each missing value is a prediction plus random variation, and the model's coefficients are themselves drawn with their uncertainty. The mice package in R uses m = 5 by default. The trial in the paper below used 50.
- Run the planned analysis, unchanged, in each dataset.
- Combine the m estimates with Rubin's rules (formula below).
Multiple imputation by chained equations (MICE) imputes one variable at a time, each from its own regression model, cycling through the variables. It assumes MAR. If the data are MNAR, its bias can be as large as that of complete cases. Leaving the outcome out of the imputation model is a known error: in the QRISK example described by Sterne and colleagues, it contributed to an unexpected null association between cholesterol and cardiovascular risk.
Interactive
Change who drops out and watch complete cases, LOCF and multiple imputation against the true difference
A made-up trial in which the whole truth is known, analysed the four ways used in real papers.
Try this: start at 25% missing on placebo and 15% on the drug, with MAR dropout. Multiple imputation gives −2.50 against the true −2.41, while complete cases give −1.36 with a CI that includes 0. Then choose MNAR: multiple imputation moves to −1.99.
Teaching example with made-up data: 100 patients per arm, depression score at baseline, week 6 and week 12 (lower is better). Some week-12 scores are missing. Estimate = drug mean minus placebo mean at week 12, with 95% CI.
Patients whose score was still high at week 6 are more likely to stop attending. The week-6 score is recorded, so it can be used.
| Analysis | Difference (95% CI) | p |
|---|---|---|
| All patients (only possible in a simulation) | −2.41 (−4.06 to −0.76) | 0.004 |
| Complete cases only | −1.36 (−3.00 to +0.29) | 0.105 |
| Last observation carried forward | −2.14 (−3.94 to −0.34) | 0.020 |
| Multiple imputation (20 imputations) | −2.50 (−4.28 to −0.72) | 0.006 |
Missing week-12 scores: 25 on placebo, 15 on the drug
Missing data in trials
If outcomes are missing, is your analysis still intention to treat?
Intention to treat means analysing every randomised patient in the group they were allocated to. A patient without an outcome can be included only by making an assumption about that missing outcome.
- Prevention comes first. The NRC panel concluded that there is no foolproof way to analyse substantial amounts of missing data, and that the key is to design and conduct the trial to limit the problem.
- Stopping treatment is not leaving the study. Too many investigators stop recording outcomes when a patient stops the drug. Continuing to measure these patients keeps an intention-to-treat analysis possible.
- ICH E9(R1) makes the same distinction. Discontinuing randomised treatment is an intercurrent event, handled in the definition of the question (the estimand). Withdrawal from the study gives missing data, handled in the analysis.
- Recruiting extra patients does not fix it. Inflating the sample size for expected dropouts restores precision but does nothing about bias from dropouts who differ from completers.
- Report it. CONSORT 2025 asks for losses and exclusions after randomisation in each group with reasons (item 22b), who was included in each analysis (21b) and how missing data were handled (21c).
Sensitivity analysis
How do you show that the result does not depend on the MAR assumption?
Repeat the analysis under different, plausible assumptions about the missing values and see whether the conclusion changes.
ICH E9(R1) defines a sensitivity analysis as a series of analyses that explore whether the inferences from the main estimator still hold when its underlying assumptions are not met, and gives tipping point analysis as an example. Common approaches:
- Best-worst and worst-best case: give all missing patients in one group a good outcome and in the other a bad one, then reverse. This shows the widest range of uncertainty for a yes/no outcome (Jakobsen et al., 2017).
- Delta adjustment (offset): assume that patients who dropped out have a mean outcome that differs by δ from similar patients who stayed, impute with that shift, and vary δ. The NRC panel describes this pattern-mixture approach.
- Tipping point: increase δ until the conclusion changes, then judge whether a difference that large is clinically plausible.
- Complete cases alongside multiple imputation: report both. Where they differ, Sterne and colleagues advise explaining why.
Interactive
Make the missing drug-arm patients worse and find the tipping point
Each step re-imputes the missing scores with a shift added. The tipping point is the smallest shift at which the 95% CI includes zero.
Try this: move the shift from 0 upwards and watch the upper end of the confidence interval. Stop where it reaches 0: that shift is the tipping point.
Same made-up trial as above, with 25% of placebo and 15% of drug week-12 scores missing (MAR dropout). Shift = how many points worse the missing drug-arm patients are assumed to be than the imputation model predicts. Each shift re-runs 20 imputations.
0 = the MAR assumption. Larger = missing patients did worse
At a shift of 0.0 points the confidence interval still excludes 0, so the conclusion that the drug lowers the score holds. Tipping point: 4.2 points. Ask whether missing patients doing that much worse is clinically plausible.
Decide
Which approach fits your missing data?
Answer two or three questions. Each answer links to the section that explains it.
Where are the values missing?
Handling missing data: all possible answers
- Complete-case analysis: Jakobsen and colleagues suggest it as the primary analysis when under about 5% is missing and particular patient groups are not lost from one arm. Report the numbers missing in each group.
- Multiple imputation under MAR: Include the outcome, every variable in the analysis and the variables that predict missingness in the imputation model. Then test the MAR assumption with sensitivity analyses.
- Complete cases, then sensitivity analyses: With missing values only in the outcome and no auxiliary variables, complete-case analysis may be the primary analysis (Jakobsen et al.). Check the conclusion with best-worst and worst-best or delta-adjusted analyses.
- Complete cases need not be biased: Missing predictor values do not bias a complete-case analysis if the reasons are unrelated to the outcome (Sterne et al.). You still lose precision, which multiple imputation can recover.
- Mixed model or multiple imputation: Use every visit each patient attended. Mixed models and multiple imputation can be valid under MAR. Do not carry the last value forward.
Comparison
Complete-case analysis or multiple imputation: which should you report?
Usually both, with one named as the primary analysis in the protocol.
| Feature | Complete-case analysis | Multiple imputation |
|---|---|---|
| Patients used | Only those with every variable recorded | Everyone, with missing values filled in several times |
| Unbiased when | Data are MCAR, or in the special cases above | Data are MAR and the imputation model includes the predictors of missingness |
| Standard errors | Correct for the patients analysed | Include the uncertainty about the missing values (Rubin's rules) |
| Work needed | None: the software default | An imputation model, a chosen number of imputations, checks of imputed values |
| If data are MNAR | Biased | Can be as biased as complete cases |
| Reporting | Numbers excluded in each group and why | Imputation model variables, method, number of imputations, and the complete-case result for comparison |
The formula
Rubin's rules: combining the results of m imputed datasets
Average the estimates, and add the variation between imputations to the average variance within them.
Q̄ = (1/m) Σ Qᵢ · W̄ = (1/m) Σ SEᵢ² · B = Σ(Qᵢ − Q̄)² ÷ (m − 1)
T = W̄ + (1 + 1/m) × B · SE = √T
- Qᵢ, SEᵢ
- estimate and standard error from imputed dataset i
- W̄
- within-imputation variance: the uncertainty there would be with complete data
- B
- between-imputation variance: the extra uncertainty because values were missing
- df
- Rubin (1987): (m − 1) × (1 + W̄ ÷ [(1 + 1/m)B])². The mice package in R uses the Barnard-Rubin small-sample version
Worked example: five imputations
Made-up teaching numbers. Difference in week-12 depression score (drug − placebo) from five imputed datasets:
| Imputation | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Estimate Qᵢ | −3.1 | −2.6 | −3.4 | −2.9 | −2.5 |
| SEᵢ | 1.10 | 1.05 | 1.12 | 1.08 | 1.06 |
- Q̄ = (−3.1 − 2.6 − 3.4 − 2.9 − 2.5) ÷ 5 = −2.90.
- W̄ = (1.10² + 1.05² + 1.12² + 1.08² + 1.06²) ÷ 5 = 1.171.
- B = [(−0.2)² + 0.3² + (−0.5)² + 0² + 0.4²] ÷ 4 = 0.54 ÷ 4 = 0.135.
- T = 1.171 + 1.2 × 0.135 = 1.333, so SE = 1.155. Using the average SE alone (√1.171 = 1.082) would understate the uncertainty.
- df = 4 × (1 + 1.171 ÷ 0.162)² = 271, critical t = 1.969.
−2.90 ± 1.969 × 1.155 → 95% CI −5.17 to −0.63, p = 0.013
The share of the total variance due to missing data, (1 + 1/m)B ÷ T, is 0.162 ÷ 1.333 = 12% here. The mice package reports it as lambda.
In a real paper
Multiple imputation and a tipping-point analysis in a randomised trial
Guillaumier A, Spratt NJ, Pollack M, Baker A, Magin P, Turner A, et al. Evaluation of an online intervention for improving stroke survivors' health-related quality of life: A randomised controlled trial. PLoS Med. 2022;19(4):e1003966.
doi:10.1371/journal.pmed.1003966 · PMID 35439246 · Free full text (PMC9017949)
The study: A randomised trial of an online healthy-lifestyle programme in 399 stroke survivors in Australia. The primary outcome, self-rated health on the EQ-VAS (0 to 100) at 6 months, was missing for 15 of 200 control and 28 of 199 intervention participants.
“Missing data were assumed to be missing at random (MAR). Multiple imputation using the chained regression equation method with 50 imputations was used. Model estimates were pooled across imputations using Rubin’s method.”
The authors assumed that, once the recorded variables were taken into account, whether a participant's 6-month score was missing did not depend on the score itself (MAR). They filled in the missing values 50 times with chained equations (MICE), ran the analysis in each of the 50 datasets, and combined the results with Rubin's rules. They then tested the MAR assumption with a tipping-point analysis.
| Reported | Value | What it means |
|---|---|---|
| Participants with the 6-month outcome | 185 of 200 control, 171 of 199 intervention | 356 of 399 (89%); more were lost from the intervention group |
| Median EQ-VAS difference, complete cases | 5.00 (0.79, 9.21), p = 0.020 | Median quantile regression in the 356 participants with follow-up |
| Same analysis after multiple imputation | 4.64 (0.12, 9.16), p = 0.044 | Pooled over 50 imputed datasets under MAR: slightly smaller, lower limit close to 0 |
| Tipping point | shift parameter of −3 | If participants with missing data scored 3 points lower than MAR predicts, the difference would lose statistical significance |
- Losses were unequal: 28 in the intervention group against 15 in the control group. The authors wrote that a 3-point difference between those with and without data "is not unrealistic".
- Compare the complete-case and imputed results: the conclusion held under MAR, but the tipping point was small, so it may not hold if the data are MNAR.
- The primary analysis changed from linear regression in the protocol to median quantile regression, because the residuals were skewed and heteroskedastic. Check the stated reason for any change of analysis.
How to run it
How to run multiple imputation
Every step below was checked against the official documentation. Steps that could not be checked are left out.
R (mice package)
library(mice) md.pattern(d) # display the missing-data patterns imp <- mice(d, m = 20, seed = 2029) # default m = 5; default method for numeric data is "pmm" fit <- with(imp, lm(hamd12 ~ arm + hamd0 + hamd6)) # the analysis, run in every imputed dataset summary(pool(fit)) # Rubin's rules; df with the Barnard-Rubin adjustment naniar::mcar_test(d) # Little's test of missing completely at random lm(hamd12 ~ arm, data = d) # na.action default na.omit: complete cases only
SPSS Statistics
These procedures need SPSS Statistics Professional Edition or the Missing Values option. The documentation pages retrieved give the dialog names but not the menu path, so the steps below name the dialogs.
- Little's MCAR test: in the Missing Value Analysis dialog box, click EM, then OK. The test appears in footnotes to each EM estimate table. Its null hypothesis is that the data are missing completely at random.
- Analyze Patterns (a Multiple Imputation procedure): select at least two analysis variables. The output can include a summary of missing values, the patterns of missing values, and the variables with the highest percentage missing.
- Impute Missing Data Values (Multiple Imputation): select at least two variables for the imputation model, set the number of imputations (default 5), and name a dataset or file for the imputed data. The new dataset contains the variable Imputation_ (0 for the original data), which SPSS defines as a split variable.
- Run the planned analysis on the imputed dataset. Procedures that support pooling, such as the Independent-Samples T Test, automatically give results for each imputation, the original data and pooled results.
DATASET DECLARE imputedData. MULTIPLE IMPUTATION hamd0 hamd6 hamd12 /IMPUTE METHOD=AUTO NIMPUTATIONS=20 /OUTFILE IMPUTATIONS = imputedData.
jamovi
The jamovi documentation checked for this chapter gives no steps for multiple imputation. The BSS module in the jamovi library lists “missing value analysis and data imputation using the missRanger and MICE” among its features, but its documentation gives no step-by-step instructions, so none are given here.
How to report it
What to write about missing data
Numbers missing in each group and why, the assumption, the method with enough detail to repeat it, and a sensitivity analysis.
Methods:
“Week-12 scores were assumed to be missing at random given baseline and week-6 scores. Missing scores were imputed 20 times from a linear regression on baseline and week-6 scores within each arm, and estimates were combined with Rubin's rules. In a sensitivity analysis, imputed scores in the drug arm were made progressively worse to find the shift at which the conclusion changed.”
Results (the trial in the interactive elements):
“Week-12 scores were missing for 25 of 100 patients on placebo and 15 of 100 on the drug. After multiple imputation the difference was −2.50 points (95% CI −4.28 to −0.72). The complete-case estimate was −1.36 (−3.00 to 0.29). The 95% CI included zero if missing drug-arm patients were assumed to score 4.2 points worse than predicted.”
Sterne and colleagues (2009) also ask authors to report the number of imputed datasets and the variables in the imputation model, to compare patients with and without missing data, and, where possible, to give the complete-case results for comparison.
By specialty
Missing data problems by specialty
A diabetes registry has HbA1c missing more often in patients from rural centres. Within a centre, testing does not depend on the HbA1c value.
Missing at random given the centre. Include the centre in the imputation model or in the analysis.
Patient-reported function one year after knee replacement. Patients with poor results return the questionnaire less often.
Likely missing not at random. Report reasons for non-return, compare baseline scores of responders and non-responders, and run a sensitivity analysis.
Pain scores at 24 hours are missing for patients who were still sedated in the ICU.
Missingness is linked to how unwell the patient was. Record ICU stay and sedation so they can enter the imputation model, and state the assumption.
Growth follow-up at 2 years is missing for families who moved away for work.
If moving is unrelated to growth, the loss may be close to MCAR. Compare baseline weight and age of those lost and those followed.
Birth weight is missing for most home deliveries in a record-based study.
Home deliveries differ from hospital deliveries. A complete-case analysis describes hospital births only. Say so, or impute using place of delivery and other recorded factors.
A 12-week antidepressant trial loses more patients on placebo, mostly those not improving.
Dropout depends on how patients are doing. Plan multiple imputation using the interim scores, keep collecting outcomes after treatment stops, and test the result with a tipping-point analysis.
In a household survey, the income question is left blank more often by the richest households.
Missing not at random. Mean imputation would understate the spread of income. Report the missing proportion and use a sensitivity analysis.
Quality-of-life scores at 6 months are not available for patients who died.
These are not missing data in the usual sense: quality of life has no meaning after death. Define the question (estimand) to allow for death, instead of imputing a score.
Common myths
Common mistaken beliefs
Myth: Missing at random means the missing patients are just like the others.
MAR means missingness depends only on recorded variables. The missing patients may be very different, for example older.
Myth: Under 5% missing never matters.
The rule of thumb (Jakobsen et al., 2017) also requires that particular patient groups are not lost from one of the compared groups.
Myth: Filling gaps with the mean is harmless.
It lowers the SD: in the teaching example from 19.9 to 10.3 mmHg. Single imputation often underestimates variability.
Myth: LOCF is always conservative.
The EMA guideline states that in some situations LOCF does not produce conservative estimates, and in a worsening disease it is likely to be optimistic.
Myth: Multiple imputation fixes any missing data.
It assumes MAR. When data are MNAR its bias can be as big as or bigger than that of complete cases (Sterne et al., 2009).
Myth: Recruiting 20% extra patients deals with dropout.
It restores the sample size, not the comparability of the groups. Bias from dropouts who differ is unchanged (NRC panel).
Myth: A test can show which mechanism you have.
Little's test can detect departures from MCAR, but MAR and MNAR cannot be distinguished using the observed data.
Why this matters to you
Five consequences of mishandling missing data
Protocol sent back
A protocol needs the expected losses, how they will be prevented, the primary method for missing data and the sensitivity analysis.
A thesis result on a biased subset
Software drops incomplete patients without warning. The analysed patients may no longer be the randomised groups.
Questions you cannot answer at the viva
"How many were lost from each group, why, and what did you assume about them?" needs numbers and a reason.
Misreading papers
Of 73 trials in top journals with missing outcomes, 45% used complete cases and 8% multiple imputation for the primary analysis (Bell et al., 2014). Many results rest on untested assumptions.
Harm to patients
When data are not MCAR, complete-case analysis risks overestimating benefit and underestimating harm (Jakobsen et al., 2017).
History
History of methods for missing data
- 1976
Donald Rubin
Published "Inference and missing data" in Biometrika, the framework of missing-data mechanisms behind the terms used today.
- 1987
Donald Rubin
Published Multiple Imputation for Nonresponse in Surveys, the source of the combining rules now called Rubin's rules.
- 2007
STROBE initiative
The STROBE statement for observational studies asked authors to explain how missing data were addressed and to report the number of participants with missing data for each variable.
- 2009
Jonathan Sterne and colleagues
Found 59 articles using multiple imputation in four general medical journals from 2002 to 2007. Only seven fully reported both imputed and complete-case results.
- 2010
European Medicines Agency
Adopted the Guideline on Missing Data in Confirmatory Clinical Trials (in force from 1 January 2011), with cautions on LOCF.
- 2012
Roderick Little and colleagues
Summarised in the NEJM the National Research Council panel report requested by the FDA in 2008: prevent missing data, avoid LOCF as the primary method, and run sensitivity analyses.
- 2019
ICH
Adopted the E9(R1) addendum on estimands and sensitivity analysis (20 November 2019), separating intercurrent events from missing data.
- 2025
CONSORT 2025 group
Added item 21c to the trial reporting checklist: how missing data were handled in the analysis.
Guidelines
Missing data in guidelines
“How missing data were handled in the analysis.” “For each group, losses and exclusions after randomisation, together with reasons.”
“Explain how missing data were addressed.” “Indicate the number of participants with missing data for each variable of interest.”
Missing data: “Data that would be meaningful for the analysis of a given estimand but were not collected.”
“Only under certain restrictive assumptions does LOCF produce an unbiased estimate of the treatment effect.”
Single-imputation methods such as LOCF should not be used as the primary approach “unless the assumptions that underlie such methods are scientifically justified.”
Reading a paper
Five checks on how a paper handled missing data
- Are the numbers with missing outcome data given for each group, with reasons?
- Is the assumed mechanism (MCAR, MAR, MNAR) stated, and is it plausible for how the data were collected?
- Which method was used? Single imputation such as LOCF or mean imputation needs a stated justification.
- For multiple imputation: are the number of imputations and the variables in the imputation model reported?
- Is there a sensitivity analysis under other assumptions, and does the conclusion survive it?
Why is it called that?
Word surgery
“Random”
Haphazard, without any pattern.
In "missing at random", missingness may follow a clear pattern (older patients miss visits) as long as that pattern is explained by recorded variables.
“Imputation”
Blaming someone, attributing a fault.
Filling in a missing value with an estimated one. Multiple imputation does this several times to show the uncertainty.
MCAR: missing for no reason. MAR: missing for a reason you recorded. MNAR: missing for a reason you did not record, often the missing value itself.
Impute
Latin imputare: "to reckon, make account of, charge, ascribe"
To bring a value into the reckoning: a missing value is replaced by an estimate.
Attrition
Latin atterere: "to wear, rub away"
The loss of participants from a study over time. Attrition bias arises when those lost differ from those who stay.
MCAR, MAR, MNAR
Missing Completely At Random · Missing At Random · Missing Not At Random
The three mechanisms. Read them as statements about what missingness depends on, not about whether the missing patients are typical.
Exam answers
Short-note outlines
Types of missing data, with clinical examples
- Definition: missing data are values that would be meaningful for the analysis but were not collected (ICH E9(R1)). A quality-of-life score after death is not missing data in this sense.
- MCAR: missingness unrelated to any patient characteristic. Example: a freezer failure destroys a batch of samples. Complete-case analysis is unbiased but less precise.
- MAR: missingness depends only on recorded variables. Example: older patients miss follow-up and age is recorded. Multiple imputation or mixed models using age are unbiased.
- MNAR: missingness depends on the missing value itself. Example: patients whose depression worsens stop attending. Only sensitivity analyses can address it.
- Key point: MAR and MNAR cannot be distinguished from the observed data. The assumption is argued from how the data arose.
- Prevention: minimise losses at the design stage, record reasons for missing values, and keep measuring patients who stop treatment.
Methods of handling missing data, with merits and demerits
| Method | What it does | Merits | Demerits |
|---|---|---|---|
| Complete-case (listwise) | Drops patients with any missing value | Simple. Unbiased under MCAR | Loses patients. Biased if not MCAR |
| Mean imputation | Replaces each gap with the variable's mean | Keeps n | Reduces the SD. SEs too small |
| LOCF / BOCF | Carries the last (or baseline) value forward | Simple in repeated measures | Assumes no change after dropout. Bias in either direction. SEs too small |
| Multiple imputation | m datasets with plausible values, combined by Rubin's rules | Uses all data. Unbiased under MAR. SEs include the uncertainty about missing values | Needs a correct imputation model. Biased under MNAR |
| Mixed models (repeated measures) | Uses every observed visit | Valid under MAR if correctly specified | Needs a statistician. Still assumes MAR |
Rubin's rules: T = W̄ + (1 + 1/m)B. Worked example: five estimates with mean −2.90, W̄ 1.171, B 0.135, SE 1.155, 95% CI −5.17 to −0.63.
Missing data and sensitivity analysis in randomised trials
- ITT and missing outcomes: analysing all randomised patients requires an assumption about those without an outcome.
- Treatment discontinuation vs withdrawal: ICH E9(R1) treats stopping treatment as an intercurrent event (part of the estimand) and study withdrawal as missing data.
- Primary analysis: usually multiple imputation or a mixed model under MAR. The NRC panel advises against LOCF as the primary method unless its assumptions are justified.
- Sensitivity analyses: best-worst and worst-best cases, delta-adjusted imputation, tipping-point analysis, and complete-case results alongside.
- Example: Guillaumier et al. (PLoS Med 2022): 50 imputations under MAR gave 4.64 (0.12 to 9.16). The result would lose significance at a shift of −3 points.
- Reporting: CONSORT 2025 items 21b, 21c, 21d and 22b.
The one thing to remember
Prevent missing data first. Then state why values are missing, analyse under a stated assumption, and show whether the conclusion changes when that assumption is wrong.
The worked example, figures and interactive elements use made-up numbers for teaching. Every statistic was computed in Python (SciPy 1.15, statsmodels 0.14) or checked against it.
Sources: Guillaumier A et al. PLoS Med 2022;19(4):e1003966 (doi:10.1371/journal.pmed.1003966, PMID 35439246). Sterne JAC, White IR, Carlin JB, et al. BMJ 2009;338:b2393 (doi:10.1136/bmj.b2393, PMID 19564179). Little RJ, D'Agostino R, Cohen ML, et al. N Engl J Med 2012;367(14):1355–60 (doi:10.1056/NEJMsr1203730, PMID 23034025). Jakobsen JC, Gluud C, Wetterslev J, Winkel P. BMC Med Res Methodol 2017;17:162 (doi:10.1186/s12874-017-0442-1, PMID 29207961). Bell ML, Fiero M, Horton NJ, Hsu CH. BMC Med Res Methodol 2014;14:118 (doi:10.1186/1471-2288-14-118, PMID 25407057). Rubin DB. Biometrika 1976;63(3):581–92 (doi:10.1093/biomet/63.3.581). Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987 (doi:10.1002/9780470316696). van Buuren S, Groothuis-Oudshoorn K. J Stat Softw 2011;45(3) (doi:10.18637/jss.v045.i03). von Elm E et al. STROBE statement. PLoS Med 2007;4(10):e296 (PMID 17941714); Vandenbroucke JP et al. STROBE explanation and elaboration. PLoS Med 2007;4(10):e297 (PMID 17941715). Hopewell S et al. CONSORT 2025 statement. BMJ 2025;389:e081123 (PMID 40228833). ICH E9(R1) addendum on estimands and sensitivity analysis, 20 November 2019. European Medicines Agency. Guideline on Missing Data in Confirmatory Clinical Trials. EMA/CPMP/EWP/1776/99 Rev. 1, 2010. R documentation for mice, naniar and stats, accessed 15 September 2026.
Further reading: Indrayan A, Malhotra RK. Medical Biostatistics. 4th ed. Boca Raton: CRC Press; 2018. ISBN 978-1-4987-9953-9.